AKT1 and meningioma: Brastianos et al., using next-generation sequencing, showed that other genetic aberrations may be found in NF2-negative meningiomas, including mutations in KDM5C, KDM6A, and SMARCB1 in 8% of patients, and the other six patients exhibited mutations of the PI3K–AKT–mTOR pathway, of whom five harbored AKT1 mutations, and one, a novel MTOR mutation (p.Glu17Lys) [8].